Karen C. Drayer Wildlife Health Center, School of Veterinary Medicine, University of California, Davis, CA 95616, USA,
Veterinary Services, Houston Zoo, Inc, Houston, TX 77030, USA,
J Zoo Wildl Med. 2022 Mar;53(1):232-240. doi: 10.1638/2021-0096.
Novel diagnostic and therapeutic methods were utilized in the successful management of severe elephant endotheliotropic herpesvirus hemorrhagic disease (EEHV-HD) in a 1.9-yr-old captive Asian elephant (). High levels of EEHV1A viremia were detected for 12 d. In addition to established EEHV treatments, therapies included famciclovir-fortified elephant whole blood and plasma, mesenchymal stem cells harvested from elephant umbilical tissue, and aminocaproic acid. Testing conducted to examine the effects of EEHV infection on hemostasis suggested marked intravascular coagulation with decreased plasminogen activity and increased D-dimer concentrations. Thromboelastography was used to assess the efficacy of aminocaproic acid and demonstrated hypofibrinolysis on samples taken after drug administration, as compared with samples from healthy adult Asian elephants. A serological assay for a novel EEHV1A-specific antibody marker (E52) was developed due to lack of seroconversion to a previously established EEHV1A-specific antibody marker (ORFQ) and showed a sustained increase after EEHV-HD illness.
新型诊断和治疗方法成功用于治疗一只 1.9 岁圈养亚洲象（）的严重象内皮细胞嗜性疱疹病毒出血性疾病（EEHV-HD）。检测到高水平的 EEHV1A 病毒血症持续了 12 天。除了已确立的 EEHV 治疗方法外，治疗还包括法昔洛韦强化的象全血和血浆、从象脐带组织中采集的间充质干细胞，以及氨基己酸。为研究 EEHV 感染对止血的影响而进行的检测表明，存在明显的血管内凝血，纤溶酶原活性降低，D-二聚体浓度升高。血栓弹性描记术用于评估氨基己酸的疗效，并与健康成年亚洲象的样本相比，在给药后样本中显示出低纤维蛋白溶解作用。由于未能针对先前建立的 EEHV1A 特异性抗体标志物（ORFQ）发生血清转化，因此开发了一种针对新型 EEHV1A 特异性抗体标志物（E52）的血清学检测方法，并在 EEHV-HD 疾病后持续增加。
